Sector News

Bristol-Myers Squibb Gets Option To Buy Galecto Biotech

November 4, 2014
Life sciences
(RTTNews.com) – Bristol-Myers Squibb Co. Monday said it has received the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead investigational product TD139, a new inhaled inhibitor of galectin-3, in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.
 
The deal value has the potential to reach $444 million, which includes the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments.
 
As per the agreement, Bristol-Myers can exercise the option to buy Galecto at any time following the execution of the transaction agreement, but no later than 60 days following completion of the Phase 1b trial. The companies have agreed on pre-clinical trials and a Phase 1 development plan, which will be executed by Galecto during the option period.
 
Francis Cuss, chief scientific officer of Bristol-Myers Squibb said: “…TD139 provides Bristol-Myers Squibb an opportunity to advance the company’s fibrosis development program with the addition of a promising compound that has the potential to modulate multiple disease pathways.”

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”